Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 766

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 766
---
 of December 31, 2024.

Holders
of the Common Stock are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon
liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and
privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and
dissolution of the Company. The holders have no preemptive or other subscription rights.

Preferred
Stock

As
of December 31, 2024, the Company has authorized the issuance of up to 1,000,000 shares of Conduit Pharmaceuticals, Inc. preferred stock
(the “Preferred Stock”). As of December 31, 2024, and December 31, 2023, no preferred shares were issued and outstanding.

At-the-Market
Offering

On
October 23, 2024, the Company entered into the Sales Agreement with A.G.P. relating to shares of the Company’s Common Stock. In
accordance with the terms of the Sales Agreement, the Company may offer and sell shares of our Common Stock having an aggregate offering
price of up to $3.6
million from time to time through A.G.P.,
acting as our sales agent or principal.

The
compensation to A.G.P. for sales of common stock sold pursuant to the Sales Agreement will be equal to 3.0% of the gross proceeds of
any shares of common stock sold under the sales agreement.

During
the year ended December 31, 2024, the Company sold 323,273
shares of Common Stock under the Sales Agreement
and generated $3.3
million in net proceeds after paying fees
to A.G.P. and other issuance costs of $0.2
million. See Note 20 for information on the issuances
and increases to the aggregate offering price subsequent to December 31, 2024.

    F-30

14.
Earnings/(Net Loss) Per Share

The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):

Schedule
of Basic and Diluted Net Loss Per Share

    2024  
    2023 

    For
                                            the years ended
                                                                               December 31, 

    2024  
    202